Is it appropriate to initiate finerenone in a patient with an estimated glomerular filtration rate of 18 mL/min/1.73 m²?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Not Initiate Finerenone at eGFR 18 mL/min/1.73 m²

Finerenone should not be started in a patient with an eGFR of 18 mL/min/1.73 m² as this falls below the established initiation threshold of ≥25 mL/min/1.73 m² 1, 2.

Initiation Threshold

The 2026 AHA/ACC/ADA/ASN guideline explicitly states that finerenone has an eGFR initiation threshold of ≥25 mL/min/1.73 m² 1. The ASN Kidney Health Guidance reinforces this, specifying that finerenone should be stopped when eGFR falls below 15 mL/min/1.73 m² 2. With an eGFR of 18 mL/min/1.73 m², this patient falls in the narrow window where continuation might be considered if already on therapy, but initiation is contraindicated.

Key Distinction: Continuation vs. Initiation

There is critical nuance here that affects clinical decision-making:

  • Continuation below threshold: Major clinical trials allowed finerenone to be continued after eGFR dropped below the 25 mL/min/1.73 m² initiation threshold, with ongoing benefit and no apparent increased adverse effects 1

  • New initiation: However, these benefits apply to patients already established on therapy, not to new starts at such low eGFR levels. The FIDELITY meta-analysis showed directionally similar cardiovascular benefit in CKD G4 (eGFR 15-29 mL/min/1.73 m²), but this was nonsignificant and requires further investigation 1

Safety Concerns at Low eGFR

Hyperkalemia risk increases substantially at lower eGFR levels 1, 2. The FIDELITY analysis specifically noted that hyperkalemia was more frequent in patients with CKD G4 treated with finerenone 1. At eGFR 18, the patient has:

  • Severely reduced potassium excretion capacity
  • Likely already on RAS inhibitors (which further increase hyperkalemia risk)
  • Limited ability to tolerate additional potassium-elevating medications

Clinical Algorithm

If this patient has compelling indications for mineralocorticoid receptor antagonism:

  1. Optimize existing kidney-protective therapies first: Ensure maximal tolerated doses of RAS inhibitors and SGLT2 inhibitors (which can be initiated at eGFR ≥20 mL/min/1.73 m²) 1, 2

  2. Monitor trajectory: If eGFR improves above 25 mL/min/1.73 m² with optimization of other therapies, finerenone initiation could be reconsidered

  3. Consider alternative MRA: If mineralocorticoid receptor antagonism is absolutely necessary, this would require extremely careful monitoring and is generally not recommended at this eGFR level

  4. Prepare for renal replacement therapy: At eGFR 18, focus should shift toward preparing for dialysis or transplant evaluation

Bottom Line

The evidence-based initiation threshold exists for patient safety. Starting finerenone at eGFR 18 mL/min/1.73 m² contradicts current guideline recommendations and exposes the patient to unacceptable hyperkalemia risk without established benefit at this level of kidney function 1, 2.

Related Questions

What are the recommended doses of finerenone (Firialta) and eplerenone for a male patient with impaired renal function (eGFR 38 ml/min/1.73 m²)?
How should finerenone be initiated, dosed, and monitored in adults with chronic kidney disease and non‑diabetic proteinuria who are already receiving a maximally tolerated ACE inhibitor or angiotensin receptor blocker?
What are the indications, dosing regimen, contraindications, and monitoring requirements for finerenone in adults with chronic kidney disease and type 2 diabetes?
Is finerenone indicated for patients with type 1 diabetes and diabetic kidney disease, especially those already on an ACE inhibitor or ARB?
What are the indications for Kerendia (finerenone) in adult patients with chronic kidney disease and type 2 diabetes, an estimated glomerular filtration rate (eGFR) of 25–90 mL/min/1.73 m², albuminuria, and serum potassium ≤5.0 mEq/L?
Does ramelteon have any specific drug interactions with carbidopa/levodopa, duloxetine, omeprazole, ezetimibe (Zetia), and ropinirole (Requip)?
What is the appropriate management for a 25-year-old male with intermittent epigastric burning pain that only partially improves with omeprazole, no alcohol use, and a recent stress trigger?
What is the appropriate evaluation and management of spontaneous scar‑like macules in a patient with livedo racemosa?
What are the treatment options for orthostatic hypotension and supine hypertension?
In a patient with a TOAST type 1 ischemic stroke, how long should aspirin (acetylsalicylic acid) and clopidogrel be administered together?
How should phentermine 15 mg be dosed when planning to increase to the next dose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.